Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)
Scope of the Report
The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)” provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Pfizer Inc, Merck & Co, Allergan Inc and Alcon (Division of Novartis) are profiled in the report.
Merck & Co,
Allergan Inc and
Alcon (Division of Novartis)
Glaucoma, the second most common cause of blindness worldwide is generally characterized by relatively high intraocular pressure (IOP) as a result of impaired drainage of fluid, known as aqueous humor, from the eye. Currently approved treatments for glaucoma include a number of pharmaceutical drugs, laser therapies and surgical procedures. Glaucoma treatment forms a significant portion of the overall eye care market.
The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years.
The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug.
Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed.